Synergistic effect of GRA7 and profilin proteins in vaccination against chronic Toxoplasma gondii infection

Arcon, Nadia; Picchio, Mariano S.; Fenoy, Ignacio Martín; Moretta, Rosalía; Soto, Ariadna Soledad; Sibilia, Matías Damián Perrone; Sánchez, Vanesa Roxana; Prato, Cecilia A.; Tribulatti, María Virginia; Goldman, Alejandra; Martin, Valentina

doi:10.1016/j.vaccine.2020.12.072

Cited by 5 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite not constituting a natural infection route, this model has the advantages of reproducibility, ease of inoculation, and accurate administration of challenge dose ( Sibley et al., 1999 ). However, variants of this procedure using other parasite stages have been also implemented, including IP injection of bradyzoites contained in tissue cysts ( Taniguchi et al., 2018 ; Gatkowska et al., 2019 ), or per os (PO) inoculation of tissue cysts ( McLeod et al., 1984 ; Khan et al., 2007 ; Taniguchi et al., 2018 ; Arcon et al., 2021 ) and oocysts ( Yang et al., 2017 ; Chiebao et al., 2021 ). These variants are inherently less reproducible due to the variable bradyzoite content of a given tissue cyst, or the difficulties in guaranteeing the oral dosage, as well as less feasible due to the complexity of oocysts production; but on the other hand, oocyst- or bradyzoite-induced infections are much more representative of what occurs in nature ( Sibley et al., 1999 ).…”

Section: In Vivo Models For Virulence Assessment: State and ...mentioning

confidence: 99%

Unifying Virulence Evaluation in Toxoplasma gondii: A Timely Task

Calero‐Bernal

Fernández‐Escobar

Katzer

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Toxoplasma gondii, a major zoonotic pathogen, possess a significant genetic and phenotypic diversity that have been proposed to be responsible for the variation in clinical outcomes, mainly related to reproductive failure and ocular and neurological signs. Different T. gondii haplogroups showed strong phenotypic differences in laboratory mouse infections, which provide a suitable model for mimicking acute and chronic infections. In addition, it has been observed that degrees of virulence might be related to the physiological status of the host and its genetic background. Currently, mortality rate (lethality) in outbred laboratory mice is the most significant phenotypic marker, which has been well defined for the three archetypal clonal types (I, II and III) of T. gondii; nevertheless, such a trait seems to be insufficient to discriminate between different degrees of virulence of field isolates. Many other non-lethal parameters, observed both in in vivo and in vitro experimental models, have been suggested as highly informative, yielding promising discriminatory power. Although intra-genotype variations have been observed in phenotypic characteristics, there is no clear picture of the phenotypes circulating worldwide; therefore, a global overview of T. gondii strain mortality in mice is presented here. Molecular characterization has been normalized to some extent, but this is not the case for the phenotypic characterization and definition of virulence. The present paper proposes a baseline (minimum required information) for the phenotypic characterization of T. gondii virulence and intends to highlight the needs for consistent methods when a panel of T. gondii isolates is evaluated for virulence.

show abstract

Section: In Vivo Models For Virulence Assessment: State and ...mentioning

confidence: 99%

Unifying Virulence Evaluation in Toxoplasma gondii: A Timely Task

Calero‐Bernal

Fernández‐Escobar

Katzer

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…Moreover, adjuvant and immunogenic potential of an rTg profilin (rTgPF) protein has been recently evaluated in a vaccine formulation in combination with the GRA7 antigen in a murine toxoplasmosis model [82]. The use of this vaccine significantly enhanced immune responses (generating a Th1-biased immunity through the induction of lymphocyte proliferation, the activation of CD4 + T cells and an increased IFN-γ production) and protection against chronic toxoplasmosis.…”

Section: Grasmentioning

confidence: 99%

“…The use of this vaccine significantly enhanced immune responses (generating a Th1-biased immunity through the induction of lymphocyte proliferation, the activation of CD4 + T cells and an increased IFN-γ production) and protection against chronic toxoplasmosis. TgPF acts as a ligand for toll-like receptor 11 (TLR11) and TLR12, inducing innate immune responses that increase type 1 adaptive responses, therefore highlighting the role of PF as a potential adjuvant in vaccine strategies against toxoplasmosis [82,83]. However, since TgProfilin interacts with TLR receptors that are not present in humans or livestock species [83,84], it appears less useful in this sense for relevant host vaccination.…”

Section: Grasmentioning

confidence: 99%

Mining the Proteome of Toxoplasma Parasites Seeking Vaccine and Diagnostic Candidates

Rashidi

Sánchez-Montejo

Mansouri

et al. 2022

Animals

View full text Add to dashboard Cite

Toxoplasma gondii is a pathogenic protozoan parasite that infects the nucleated cells of warm-blooded hosts leading to an infectious zoonotic disease known as toxoplasmosis. The infection outcomes might be severe and fatal in patients with immunodeficiency, diabetes, and pregnant women and infants. The One Health approach to toxoplasmosis highlights that the health of humans is closely related to the health of animals and our common environment. The presence of drug resistance and side effects, the further improvement of sensitivity and specificity of serodiagnostic tools and the potentiality of vaccine candidates to induce the host immune response are considered as justifiable reasons for the identification of novel targets for the better management of toxoplasmosis. Thus, the identification of new critical proteins in the proteome of Toxoplasma parasites can also be helpful in designing and test more effective drugs, vaccines, and diagnostic tools. Accordingly, in this study we present important proteins found in the proteome of the life cycle-specific stages of Toxoplasma parasites that are potential diagnostic or vaccine candidates. The current study might help to understand the complexity of these parasites and provide a possible source of strategies and biomolecules that can be further evaluated in the pathobiology of Toxoplasma parasites and for diagnostics and vaccine trials against this disease.

show abstract

“…SAG1 targeting of DEC205 endocytic receptor on dendritic cells via single-chain fragment variable antibody enhanced both cellular and humoral immune responses in mice, which contributed to strongly inhibiting brain cyst formation [ 67 ]. Effective bone marrow dendritic cell activation was observed from multi-antigen protein vaccines comprising GRA7 and T. gondii profilin compared to either antigen alone, and this enabled effective induction of humoral and cellular immunity [ 68 ].…”

Section: Vaccine Platforms Against T Gondiimentioning

confidence: 99%

Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development

Chu

Quan

2021

Vaccines

View full text Add to dashboard Cite

Toxoplasmosis, caused by the apicomplexan parasite Toxoplasma gondii, is one of the most damaging parasite-borne zoonotic diseases of global importance. While approximately one-third of the entire world’s population is estimated to be infected with T. gondii, an effective vaccine for human use remains unavailable. Global efforts in pursuit of developing a T. gondii vaccine have been ongoing for decades, and novel innovative approaches have been introduced to aid this process. A wide array of vaccination strategies have been conducted to date including, but not limited to, nucleic acids, protein subunits, attenuated vaccines, and nanoparticles, which have been assessed in rodents with promising results. Yet, translation of these in vivo results into clinical studies remains a major obstacle that needs to be overcome. In this review, we will aim to summarize the current advances in T. gondii vaccine strategies and address the challenges hindering vaccine development.

show abstract

Synergistic effect of GRA7 and profilin proteins in vaccination against chronic Toxoplasma gondii infection

Cited by 5 publications

References 38 publications

Unifying Virulence Evaluation in Toxoplasma gondii: A Timely Task

Unifying Virulence Evaluation in Toxoplasma gondii: A Timely Task

Mining the Proteome of Toxoplasma Parasites Seeking Vaccine and Diagnostic Candidates

Advances in Toxoplasma gondii Vaccines: Current Strategies and Challenges for Vaccine Development

Contact Info

Product

Resources

About